AccurEdit Therapeutics' ART001 Becomes China's First Gene Editing Therapy to Receive FDA Regenerative Medicine Advanced Therapy (RMAT) Designation
RMAT designation expected to expedite development; 72 weeks interim clinical trial data showing sustainable reduction of TTR over 90% with no significant adverse events. SUZHOU, China, May 29, 2025 /PRNewswire/ -- AccurEdit Therapeutics today...
Kexing Biopharm's GB18 project received clearance of IND application from NMPA and FDA
SHENZHEN, China, May 29, 2025 /PRNewswire/ -- On May 26th, Kexing Biopharm (688136.SH) announced that the National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application for its independently developed...
Tuniu Announces Receipt of Minimum Bid Price Notice from Nasdaq
NANJING, China, May 23, 2025 /PRNewswire/ -- Tuniu Corporation (Nasdaq: TOUR) ("Tuniu" or the "Company"), a leading online leisure travel company in China, today announced that it has received written notification from the staff of the Listing...
FDA Clearance of Investigational New Drug Application Received for Novel EGFR/HER3 Bispecific Antibody-Drug Conjugate AVZO-1418/DB-1418
Phase 1/2 first-in-human clinical study planned this year SHANGHAI and SAN DIEGO, May 23, 2025 /PRNewswire/ -- Duality Biotherapeutics ("DualityBio", HKEX:09606) partner Avenzo Therapeutics, Inc. ("Avenzo"), a clinical-stage biotechnology company...
Wafra Named Euromoney's Best Islamic Fund Manager for Second Consecutive Year
NEW YORK, May 21, 2025 /PRNewswire/ -- Wafra Inc. ("Wafra"), a leading global alternative investment firm headquartered in New York, announced today that its Global Sukuk Team has been named Best Islamic Fund Manager1 at the 2025 Euromoney Islamic...
Modern Dairy Wins Six Awards in Extel's 2025 Asia (ex-Japan) Executive Team Rankings
HONG KONG, May 20, 2025 /PRNewswire/ -- On May 20, the prestigious financial magazine "Extel" (formerly "Institutional Investor") officially announced the results of the "2025 Asia (ex-Japan) Executive Team-SMID" rankings. The survey assessed and...
Pulnovo Medical Welcomes EQT as a New Investor Following CE-MDR Approval, with Continued Support from Qiming Venture Partners
HONG KONG, May 20, 2025 /PRNewswire/ -- Pulnovo Medical, a globally recognized pioneer in medical devices for pulmonary hypertension (PH) and heart failure (HF), has received new investment from EQT Group, a top-tier global private equity firm, as a...
WuXi XDC Received Multiple Awards from 2025 Extel (previously "Institutional Investor") Ranking in Diverse Categories
SHANGHAI, May 20, 2025 /PRNewswire/ -- WuXi XDC Cayman Inc. ("WuXi XDC", stock code: 2268.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on the bioconjugate market, today announced that the...
Çelebi Aviation Public Statement
İSTANBUL, Türkiye , May 17, 2025 /PRNewswire/ -- Dear Members of the Press, As Çelebi Aviation, transparency, adherence to ethical principles, and full compliance with legal regulations have always been at the core of our values. For over 65 years,...
Caliway Announces Successful EOP2 Meeting with the FDA for CBL-514 in Reduction of Abdominal Subcutaneous Fat
- Caliway has completed the End-of-Phase 2 (EOP2) meeting with the U.S. FDA for CBL-514, the world's first investigational drug for large-area subcutaneous fat reduction developed under the 505(b)(1) regulatory pathway. - The company has received...